Hemophilia patients with a low number of red blood cells and reduced coagulation factor levels — the activity level of proteins essential for blood clotting — are at a higher risk of increased blood loss during a knee replacement surgery, a study reported. The study, “Risk…
News
Treatment with the experimental gene therapy Roctavian (valoctocogene roxaparvovec) significantly increased factor VIII levels in men with severe hemophilia A treated in the Phase 3 GENEr8-1 trial and with reasonable safety, findings at one and two years post-treatment show. While declines in these levels were evident over time,…
Patient registries are a hot topic of rare disease research and many organizations are taking advantage of this resource by signing up their patient communities and connecting with researchers. Eric Sid, MD, program officer for the Office of Rare Diseases Research (ORDR), said it is difficult to estimate how…
A foam roller to release tension in the fascia — a casing of fibrous tissue that surrounds and holds other tissues in place — is safe to be used by patients with knee joint disease caused by hemophilia, a Spanish has study found. When the fascia tightens around muscles,…
A multi-institute research collaboration has received a $12 million grant from the National Heart Lung and Blood Institute to understand what’s behind limitations in gene therapies currently being tested in people with hemophilia A. The goal is to use this information to develop safer and long-lasting gene therapies…
Weekly use of the experimental, long-acting therapy efanesoctocog alfa safely and effectively prevents bleeds in adolescents and adults with severe hemophilia A, according to top-line, one-year data from the Phase 3 XTEND-1 trial. The therapy — being jointly developed by Sanofi and Sobi — was also superior to approved preventive therapies…
The first participant has been dosed in a Phase 1/2 dose-confirmation trial that is testing FLT180a, an experimental gene therapy that Freeline is developing to treat hemophilia B. “We are very excited about this progress in our hemophilia B program as our enhanced focus on execution is starting to…
Diabetes, which causes blood sugar levels to rise too high, is less likely to develop in young men with hemophilia than in the general male population, a U.S. study found. However, the risk of diabetes rose in older patients and in those who tested positive for hepatitis C (HCV),…
Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases. There are about 400 million people worldwide living with a rare disease; for many of them, access to diagnosis, care, and treatments can be challenging. Accessing better care depends on…
Four people in a region of Northern Italy were diagnosed with acquired hemophilia A (AHA) weeks after receiving the second dose of a vaccine against COVID-19, scientists reported. The unusually high number of newly identified acquired hemophilia A cases within eight months in the Italian province led the investigators to suspect…
Recent Posts
- How practicing gratitude helps me cope with my bleeding disorder
- Lower-dose gene therapy effective in severe hemophilia A: Study
- Our family’s travel planning looks a little different these days
- Embracing the strange signals that come with a bleeding disorder
- Who am I? A woman with a bleeding disorder. See me. Believe me. Treat me.